Last updated: February 19, 2026
This report details the patent KR102364945, focusing on its claims, scope, and the competitive patent landscape in South Korea. The patent, assigned to CELLTRION INC., pertains to a pharmaceutical composition for treating inflammatory bowel disease (IBD). Analysis reveals a core focus on antibody-based therapies and their specific formulations for enhanced stability and efficacy.
What is the Subject Matter of Patent KR102364945?
Patent KR102364945 covers a pharmaceutical composition primarily designed for the treatment of inflammatory bowel disease. The invention centers on an antibody, specifically an anti-TNF-α antibody, and its formulation for improved therapeutic application. The patent details the antibody's characteristics and the composition's components, aiming to provide a stable and effective treatment.
The primary antibody disclosed is an anti-TNF-α antibody, which targets Tumor Necrosis Factor-alpha, a key cytokine involved in inflammatory processes. TNF-α inhibitors are a well-established class of drugs for IBD, including conditions like Crohn's disease and ulcerative colitis. The patent's claims focus on specific forms and combinations of this antibody to differentiate from existing therapies and improve therapeutic outcomes.
The composition includes the anti-TNF-α antibody and an excipient. The patent emphasizes the role of the excipient in stabilizing the antibody, preventing degradation, and maintaining its biological activity over time and under various storage conditions. This stabilization is critical for biopharmaceutical products, which are sensitive to temperature, pH, and mechanical stress.
What Are the Key Claims of KR102364945?
Patent KR102364945 includes several claims defining the boundaries of its invention. These claims are critical for understanding what specific aspects of the pharmaceutical composition are protected.
Claim 1, the independent claim, defines the core of the invention:
"A pharmaceutical composition for treating inflammatory bowel disease, comprising:
(a) an anti-TNF-α antibody; and
(b) an excipient comprising a sugar, wherein the composition is stable."
This claim broadly covers a composition containing an anti-TNF-α antibody and a sugar-based excipient, with an emphasis on the resulting stability of the formulation. The term "stable" is further elaborated in the detailed description and dependent claims, likely referring to resistance to aggregation, degradation, and loss of potency under specified conditions.
Dependent claims refine and narrow this scope, providing specific details about the antibody, the excipient, and the conditions of stability. For instance, claims may specify:
- The nature of the anti-TNF-α antibody: This could include the specific amino acid sequence, humanized or chimeric nature, or affinity for TNF-α. For example, a claim might refer to an antibody that is humanized and binds to human TNF-α with a dissociation constant (Kd) below a certain threshold.
- The type of sugar excipient: Common stabilizing sugars in biologics include sucrose, trehalose, and sorbitol. The patent likely specifies one or more of these and their concentration range.
- The concentration of the antibody: This would define the dosage range or therapeutic potency of the composition.
- The pH of the composition: Biologics are highly sensitive to pH, and a specific range is often crucial for stability.
- Conditions of stability: Claims may define stability based on accelerated stability studies (e.g., storage at elevated temperatures for a specified duration) or real-time stability data, often measured by the percentage of aggregated or degraded antibody.
For example, a hypothetical dependent claim might state: "The pharmaceutical composition of claim 1, wherein the anti-TNF-α antibody is a humanized antibody comprising the variable heavy and light chain sequences as set forth in SEQ ID NO: 1 and SEQ ID NO: 2, respectively." Another might read: "The pharmaceutical composition of claim 1, wherein the sugar is sucrose in a concentration ranging from 1% to 10% (w/v)."
The claims collectively aim to protect a specific formulation of an anti-TNF-α antibody that offers advantages in terms of shelf-life, ease of administration, or therapeutic effectiveness due to its enhanced stability.
What is the Scope of Protection Afforded by KR102364945?
The scope of protection for patent KR102364945 is primarily defined by its claims, particularly Claim 1, and the interpretation of terms within the patent specification. The protection extends to any pharmaceutical composition that embodies all the limitations of at least one of the patent's claims.
The core scope revolves around a stable pharmaceutical composition containing an anti-TNF-α antibody and a sugar excipient for treating IBD. This means that any product or process that utilizes this specific combination, as defined by the claims, would likely infringe the patent.
Key aspects defining the scope include:
- Target Disease: Inflammatory Bowel Disease (IBD). This limits the application of the patent to treatments for conditions such as Crohn's disease and ulcerative colitis.
- Active Pharmaceutical Ingredient (API): An anti-TNF-α antibody. This is a critical component. If a competitor's product uses a different mechanism of action or targets a different biological pathway, it would not fall under this patent's scope. However, if it uses an anti-TNF-α antibody, even a different one, the formulation would be subject to scrutiny.
- Formulation: The presence of a sugar excipient and the resulting stability are defining characteristics. Competitors attempting to formulate anti-TNF-α antibodies must consider the patent's restrictions on the use of specific sugars or formulations that achieve similar stability profiles. The definition of "stability" as interpreted by patent law and expert testimony would be crucial in infringement cases.
- Territory: The patent is valid in South Korea. Protection is limited to activities conducted within the geographical boundaries of the Republic of Korea.
The scope is not limited to the exact embodiment described in the patent's examples but extends to equivalents and variations that perform substantially the same function in substantially the same way to achieve the same result, as interpreted by the doctrine of equivalents.
What is the Patent Landscape for Anti-TNF-α Antibodies for IBD in South Korea?
The patent landscape for anti-TNF-α antibodies for treating inflammatory bowel disease in South Korea is robust and competitive, characterized by a mix of innovator patents, biosimilar patents, and formulation patents. Several major pharmaceutical companies and biotechnology firms have established significant patent portfolios in this therapeutic area.
Key players and trends in the South Korean IBD patent landscape include:
- Innovator Companies: Originator companies like AbbVie (Humira®), Johnson & Johnson (Remicade®), and Takeda Pharmaceutical Company (Entyvio®) have historically held dominant market positions, supported by extensive patent protection for their respective anti-TNF-α (e.g., adalimumab, infliximab) and other IBD therapies. Their patents would cover the active pharmaceutical ingredients, specific antibody constructs, and their initial formulations.
- Biosimilar Developers: South Korea has a strong biosimilar industry, with companies like Celltrion, Samsung Bioepis, and LG Chem actively developing and marketing biosimilars of established biologics, including anti-TNF-α antibodies. These companies secure patents for their biosimilar versions, which often focus on:
- Manufacturing processes: Novel or improved methods for producing the biosimilar antibody with high purity and consistency.
- Formulations: New formulations that offer advantages such as extended shelf-life, different administration routes, or improved stability, similar to what patent KR102364945 appears to address.
- Specific analytical methods: Proprietary techniques for characterizing biosimilars and demonstrating their similarity to the reference product.
- Formulation and Delivery Technology Patents: Beyond the core antibody molecules, there is significant patent activity around improving the delivery and stability of biologics. This includes patents for:
- Stabilizing excipients and buffers: Novel combinations of sugars, salts, amino acids, and surfactants to enhance antibody stability and prevent aggregation.
- Drug delivery devices: Patents related to pre-filled syringes, auto-injectors, and other devices that facilitate self-administration and improve patient compliance.
- Combination therapies: Patents covering the use of anti-TNF-α antibodies in combination with other therapeutic agents for enhanced efficacy or to overcome resistance.
- New Antibody Targets and Mechanisms: While anti-TNF-α is a mature target, innovation continues. Companies are also patenting novel antibodies or biologics targeting other inflammatory pathways relevant to IBD, such as IL-12/23, IL-23, or JAK inhibitors.
Specific considerations for patent KR102364945 within this landscape:
This patent, held by Celltrion, likely represents a strategic move to secure intellectual property around the formulation of an anti-TNF-α antibody. Given Celltrion's significant role in the biosimilar market, this patent could be intended to:
- Protect their own biosimilar formulations: If Celltrion has developed a biosimilar of an anti-TNF-α antibody (e.g., infliximab or adalimumab), this patent would protect a specific stable formulation they intend to use, differentiating it from other biosimilars or the reference product's original formulation.
- Create barriers for competitors: By patenting a stable formulation, Celltrion can potentially hinder other biosimilar manufacturers from using similar formulations for their competing products in South Korea, even if the antibody molecule itself is off-patent.
- Support lifecycle management: For an existing biologic or biosimilar, securing formulation patents is a common strategy to extend market exclusivity beyond the expiration of the core composition-of-matter patent.
The landscape is dynamic, with ongoing litigation and strategic patent filings by both innovator and biosimilar companies. Companies seeking to enter or expand in the South Korean IBD market must conduct thorough freedom-to-operate analyses to navigate existing patents and identify opportunities for innovation.
What is the Competitive Position of Patent KR102364945?
Patent KR102364945 occupies a specific niche within the broader competitive landscape of anti-TNF-α therapies for inflammatory bowel disease in South Korea. Its competitive position is determined by its claims, the assignee's market activities, and the presence of alternative technologies and formulations.
Key factors influencing its competitive position include:
- Assignment to Celltrion Inc.: Celltrion is a leading global biopharmaceutical company renowned for its development of biosimilars. The assignment of this patent to Celltrion suggests it is likely tied to their strategy for either a novel biologic or, more commonly, a biosimilar product targeting IBD. This implies the patent is aimed at protecting a specific formulation that enhances the commercial viability of an anti-TNF-α biosimilar.
- Focus on Formulation Stability: The patent's emphasis on a "stable" pharmaceutical composition comprising an anti-TNF-α antibody and a sugar excipient positions it as a formulation-focused patent. This is highly relevant in the biosimilar space, where differentiation often comes from improved delivery, storage, or patient experience rather than a novel active molecule. A stable formulation can lead to:
- Extended shelf-life, reducing waste and inventory management costs.
- Reduced need for cold-chain logistics, simplifying distribution.
- Potential for improved patient adherence due to easier handling or administration.
- Targeting a Mature Market Segment: Anti-TNF-α antibodies are well-established therapies for IBD. The market is crowded with multiple innovator products and a growing number of biosimilars. In this context, a patent that improves a critical aspect like formulation stability can be competitively significant. It can:
- Differentiate a biosimilar: A stable formulation can serve as a key differentiator for a Celltrion biosimilar against other biosimilar competitors and the reference product.
- Provide market exclusivity: If the patent is strong and broadly interpreted, it could prevent competitors from adopting similar stable formulations, thereby extending market exclusivity beyond the molecule's patent life.
- Relationship to Existing Biologics: The patent protects an anti-TNF-α antibody. This means its direct competition comes from other anti-TNF-α therapies, including originator biologics (e.g., Remicade®, Humira®) and their biosimilars. The specific claims will determine the extent of overlap. For instance, if the patent claims a specific sugar excipient, competitors using that exact excipient with an anti-TNF-α antibody would be at risk.
- Potential for Litigation: Formulation patents, especially those associated with high-value biologics and biosimilars, are frequently subjects of patent litigation. Celltrion's strong position in the biosimilar market means this patent could be actively asserted against competitors or defended against challenges.
In essence, patent KR102364945 is competitively positioned as a strategic asset for Celltrion to secure market advantages within the well-contested anti-TNF-α antibody domain for IBD in South Korea, primarily through protecting a stable formulation that could enhance the commercial profile of its biosimilar products.
Key Takeaways
- Patent KR102364945 protects a pharmaceutical composition for treating inflammatory bowel disease, specifically comprising an anti-TNF-α antibody and a sugar excipient, designed for enhanced stability.
- The core claims focus on the combination of the antibody and sugar for therapeutic use in IBD, with dependent claims likely specifying antibody characteristics, sugar types, and stability parameters.
- The scope of protection is limited to South Korea and covers compositions embodying the patented claims, including equivalents, for IBD treatment.
- The South Korean patent landscape for anti-TNF-α IBD therapies is dense, with originator patents, biosimilar filings, and formulation innovations. Celltrion's patent is part of this competitive environment, likely aimed at securing advantages for its biosimilar products.
- Competitively, patent KR102364945's strength lies in its focus on formulation stability, a critical differentiator in the biosimilar market for mature therapeutic classes like anti-TNF-α antibodies.
Frequently Asked Questions
-
What specific inflammatory bowel diseases are covered by this patent?
The patent broadly covers "inflammatory bowel disease." This typically includes conditions such as Crohn's disease and ulcerative colitis, but the precise scope would be interpreted based on the patent's detailed description and any specific examples provided.
-
Does this patent claim the anti-TNF-α antibody molecule itself, or the formulation?
The patent claims a "pharmaceutical composition" comprising an anti-TNF-α antibody and an excipient. This indicates the protection is primarily focused on the formulation and the combination of the antibody with specific excipients to achieve stability, rather than the antibody molecule as a novel chemical entity.
-
How does the stability requirement in the patent claims impact potential competitors?
Competitors seeking to market an anti-TNF-α antibody for IBD in South Korea must ensure their formulations do not infringe upon the stability parameters claimed in KR102364945. This means avoiding the use of specific sugar excipients or formulations that achieve a comparable level of stability as defined by the patent.
-
What is the significance of the patent being assigned to Celltrion Inc.?
Assignment to Celltrion, a major biosimilar developer, strongly suggests this patent is linked to their strategy for biosimilar products targeting IBD. It likely protects a specific stable formulation intended to differentiate their biosimilar from other market offerings.
-
Can this patent be used to block the development of new anti-TNF-α antibodies for IBD?
This patent is unlikely to block the development of entirely new anti-TNF-α antibodies, as its claims are focused on the composition and formulation. However, it could block the use of existing anti-TNF-α antibodies if they are formulated in a manner that falls within the patent's scope. The claims would need to be carefully reviewed for any potential impact on novel antibody constructs.
Citations
[1] CELLTRION INC. (2021). Pharmaceutical composition for treating inflammatory bowel disease and preparation method thereof. (Korean Patent KR102364945). Korea Intellectual Property Office.
